GSK (GSK) said Thursday Health Canada has approved Jemperli for use in combination with chemotherapy to treat adults with primary advanced or first recurrent endometrial cancer.
The approval broadens the previous indication for Jemperli in combination with carboplatin and paclitaxel to include patients with mismatch repair proficient/microsatellite stable tumors, the company said.
Price: 36.06, Change: +0.69, Percent Change: +1.94